In Win For Merck, Panel Agrees Januvia Patent Not Anticipated, Obvious
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals ruled Sept. 29 that the Patent Trial and Appeal Board correctly confirmed as patentable various claims of a patent claiming sitagliptin...To view the full article, register now.
Already a subscriber? Click here to view full article